Coloplast A/S (OTCMKTS:CLPBY) Sets New 52-Week Low - Should You Sell?

Key Points

• Coloplast hit a new 52-week low, trading as low as $6.52 (last $6.53) — down about 4.8% from the prior close of $6.86 on volume of 2,079,355 shares.
• Analyst sentiment is tepid: Sanford C. Bernstein raised the stock to a "Hold" and the consensus rating from three analysts is an average Hold.
• Recent results were mixed: Coloplast topped EPS estimates ($0.10 vs. $0.09) but missed revenue ($1.11B vs. $1.12B); the stock trades below its 50‑day ($7.38) and 200‑day ($8.37) moving averages and has a P/E of 24.19 and PEG of 0.73.

Coloplast A/S Sponsored ADR (OTCMKTS:CLPBY - Get Free Report)'s stock price hit a new 52-week low during mid-day trading on Wednesday . The stock traded as low as $6.52 and last traded at $6.53, with a volume of 2079355 shares trading hands. The stock had previously closed at $6.86.

Analyst Ratings Changes

Separately, Sanford C. Bernstein raised Coloplast A/S to a "hold" rating in a research note on Wednesday, January 28th. Three equities research analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, Coloplast A/S has an average rating of "Hold".

Coloplast A/S Stock Down 4.8%

The firm has a market capitalization of $14.72 billion, a price-to-earnings ratio of 24.19, a P/E/G ratio of 0.73 and a beta of 0.50. The business has a 50 day simple moving average of $7.38 and a 200-day simple moving average of $8.37. The company has a debt-to-equity ratio of 1.50, a quick ratio of 0.81 and a current ratio of 1.30.

Coloplast A/S (OTCMKTS:CLPBY - Get Free Report) last issued its earnings results on Friday, February 6th. The company reported $0.10 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.09 by $0.01. Coloplast A/S had a return on equity of 27.87% and a net margin of 14.35%.The business had revenue of $1.11 billion during the quarter, compared to the consensus estimate of $1.12 billion. On average, equities analysts expect that Coloplast A/S Sponsored ADR will post 0.31 EPS for the current year.

About Coloplast A/S

Coloplast A/S is a global developer and manufacturer of medical devices and services focused on intimate healthcare. The company specializes in solutions designed to assist individuals with chronic medical conditions, aiming to improve quality of life through innovative products. Coloplast's offerings span ostomy care, continence care, wound and skin care, and interventional urology, targeting patients who require long-term support and specialized treatments.

In its ostomy business, Coloplast provides pouches, skin barriers and accessories for patients who have had surgical procedures to divert bodily waste.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.